Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-fr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Hellmann, M.D., Ciuleanu, T.-E., Pluzanski, A., Lee, J.S., Otterson, G.A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S.S., Brahmer, J., Reck, M., O’Byrne, K.J., Geese, W.J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., Paz-Ares, L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7193684/
https://ncbi.nlm.nih.gov/pubmed/29658845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1801946
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares